BRPI0920326A2 - composição e método para tratamento da síndrome do olho ressecado - Google Patents

composição e método para tratamento da síndrome do olho ressecado

Info

Publication number
BRPI0920326A2
BRPI0920326A2 BRPI0920326A BRPI0920326A BRPI0920326A2 BR PI0920326 A2 BRPI0920326 A2 BR PI0920326A2 BR PI0920326 A BRPI0920326 A BR PI0920326A BR PI0920326 A BRPI0920326 A BR PI0920326A BR PI0920326 A2 BRPI0920326 A2 BR PI0920326A2
Authority
BR
Brazil
Prior art keywords
composition
dry eye
eye syndrome
treating dry
treating
Prior art date
Application number
BRPI0920326A
Other languages
English (en)
Inventor
Louis L Wood
Vernon Wong
Original Assignee
Ramscor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ramscor Inc filed Critical Ramscor Inc
Publication of BRPI0920326A2 publication Critical patent/BRPI0920326A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
BRPI0920326A 2008-10-09 2009-10-09 composição e método para tratamento da síndrome do olho ressecado BRPI0920326A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10411008P 2008-10-09 2008-10-09
PCT/US2009/060200 WO2010042843A2 (en) 2008-10-09 2009-10-09 Composition and method for treating dry eye syndrome

Publications (1)

Publication Number Publication Date
BRPI0920326A2 true BRPI0920326A2 (pt) 2016-02-23

Family

ID=42099450

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0920326A BRPI0920326A2 (pt) 2008-10-09 2009-10-09 composição e método para tratamento da síndrome do olho ressecado

Country Status (8)

Country Link
US (3) US8722728B2 (pt)
EP (1) EP2344155B1 (pt)
JP (2) JP5731980B2 (pt)
CN (2) CN107468648A (pt)
AU (1) AU2009302167B9 (pt)
BR (1) BRPI0920326A2 (pt)
CA (1) CA2739658C (pt)
WO (1) WO2010042843A2 (pt)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2619303T3 (es) 2005-06-01 2017-06-26 Edison Pharmaceuticals, Inc. Productos terapéuticos redox activos para el tratamiento de enfermedades mitocondriales y otras afecciones y modulación de biomarcadores energéticos
WO2007100652A2 (en) 2006-02-22 2007-09-07 Edison Pharmaceuticals, Inc. Side chain variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers
MX363223B (es) 2008-09-10 2019-03-15 Bioelectron Tech Corp Tratamiento de trastornos generalizados del desarrollo con terapeuticos con actividad redox.
CN107468648A (zh) * 2008-10-09 2017-12-15 拉姆斯科股份有限公司 治疗干眼综合征的组合物和方法
CA2777479C (en) 2009-04-28 2017-10-17 Ptc Therapeutics, Inc. Treatment of leber's hereditary optic neuropathy and dominant optic atrophy with tocotrienol quinones
US20120136048A1 (en) * 2009-04-28 2012-05-31 Miller Guy M Topical, periocular, or intraocular use of tocotrienols for the treatment of ophthalmic diseases
KR20140022900A (ko) * 2011-04-22 2014-02-25 알콘 리서치, 리미티드 2종의 상이한 점도 증강제를 포함하는 점도 증강 시스템을 갖는 안과 조성물
CN113230021A (zh) 2015-01-12 2021-08-10 科达莱昂治疗公司 微滴递送设备和方法
CN107530509A (zh) 2015-04-10 2018-01-02 科达莱昂治疗公司 具有可替换安瓿的压电分配器
US10703701B2 (en) 2015-12-17 2020-07-07 Ptc Therapeutics, Inc. Fluoroalkyl, fluoroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amine 1,4-benzoquinone derivatives for treatment of oxidative stress disorders
US11478437B2 (en) 2016-07-05 2022-10-25 Jenivision Inc. Formulations for hair growth
CN107625824A (zh) * 2016-07-19 2018-01-26 姜先云 全功能渗出滴眼液中药
CN109843288A (zh) * 2016-10-21 2019-06-04 狮王株式会社 眼科用制剂和眼科用药
CN109906120A (zh) 2017-01-20 2019-06-18 科达莱昂治疗公司 压电流体分配器
KR20220153671A (ko) * 2017-06-30 2022-11-18 제니비젼 인크. 모발 성장용 제제
WO2019113483A1 (en) 2017-12-08 2019-06-13 Kedalion Therapeutics, Inc. Fluid delivery alignment system
US12350194B1 (en) 2018-04-12 2025-07-08 Bausch + Lomb Ireland Limited Topical ocular delivery of fluids with controlled mass dosing and wireless communication
US20190314197A1 (en) 2018-04-12 2019-10-17 Kedalion Therapeutics, Inc. Topical Ocular Delivery Methods and Devices for Use in the Same
CA3097926A1 (en) 2018-05-01 2019-11-07 Chibi, Inc. Eye drop formulation and method for sustained delivery of medicament to the retina
EP4670713A1 (en) 2018-05-01 2025-12-31 Chibi, Inc. LIQUID DEPOSIT FOR THE PROLONGED NON-INVASIVE ADMINISTRATION OF AGENTS TO THE IL
WO2020010116A1 (en) 2018-07-03 2020-01-09 Kedalion Therapeutics, Inc. Topical ocular delivery devices and methods for using the same
KR20210038636A (ko) 2018-07-27 2021-04-07 존슨 앤드 존슨 서지컬 비전, 인코포레이티드 눈 치료용 조성물 및 방법
US10966948B2 (en) 2019-07-23 2021-04-06 Johnson & Johnson Surgical Vision, Inc. Compositions and methods for treating the eye
DK3673896T3 (da) * 2018-12-28 2022-02-07 Dr Rolf Lambert Pharma Consulting Gmbh Liposomal øjendråbeopløsning og anvendelser deraf til behandling af tørre øjne.
US12097145B2 (en) 2019-03-06 2024-09-24 Bausch + Lomb Ireland Limited Vented multi-dose ocular fluid delivery system
US11679028B2 (en) 2019-03-06 2023-06-20 Novartis Ag Multi-dose ocular fluid delivery system
IT201900018929A1 (it) * 2019-10-15 2021-04-15 Md Italy Srl “composizione ed uso di una soluzione oftalmica a base di acido ialuronico ed arabinogalattano”
US12496218B1 (en) 2019-11-12 2025-12-16 Bausch + Lomb Ireland Limited Fractionated topical ocular drug delivery methods and devices for use in the same
US11969454B2 (en) 2019-11-19 2024-04-30 Johnson & Johnson Surgical Vision, Inc. Compositions and methods for treating the eye
US12290472B2 (en) 2020-04-17 2025-05-06 Bausch + Lomb Ireland Limited Hydrodynamically actuated preservative free dispensing system
CN115768384A (zh) 2020-04-17 2023-03-07 科达隆治疗公司 流体动力致动的不含防腐剂分配系统
US11938057B2 (en) 2020-04-17 2024-03-26 Bausch + Lomb Ireland Limited Hydrodynamically actuated preservative free dispensing system
EP4120973A4 (en) 2020-04-17 2024-04-17 Bausch + Lomb Ireland Limited Hydrodynamically actuated preservative free dispensing system having a collapsible liquid reservoir
IT202100005777A1 (it) 2021-03-11 2022-09-11 Hippocrates Res S R L Composizione per l’uso nel trattamento dell’occhio secco
KR20240109779A (ko) * 2023-01-05 2024-07-12 주식회사 종근당 리피테그라스트와 토코페롤을 함유하는 건성안 예방 또는 치료용 약제학적 조성물

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62106018A (ja) * 1985-11-01 1987-05-16 Santen Pharmaceut Co Ltd 高濃度ビタミンｅ水性製剤
CN1129400A (zh) 1994-05-06 1996-08-21 阿尔康实验室公司 维生素e生育酚衍生物在眼科组合物中的应用
JPH09157165A (ja) * 1995-12-11 1997-06-17 Lion Corp 点眼薬及び白内障の遅延・治療用剤
ITMI981586A1 (it) * 1998-07-10 2000-01-10 Giorgio Panin Vitamina e e suoi esteri per l'uso nel trattamento topico di patologie delle mucose
US6048891A (en) 1998-12-17 2000-04-11 Loma Linda University Medical Center Use of γ-tocopherol and its oxidative metabolite LLU-α in the treatment of natriuretic disease
US6716451B1 (en) * 1999-11-30 2004-04-06 Soft Gel Technologies, Inc. Formulation and delivery method to enhance antioxidant potency of vitamin E
KR100365678B1 (ko) 2000-03-24 2002-12-26 주식회사 엘지생명과학 주사능이 개선된 소마토트로핀 조성물
JP2004059432A (ja) * 2002-06-04 2004-02-26 Rohto Pharmaceut Co Ltd 角膜障害治療剤
JP2004323486A (ja) * 2003-04-30 2004-11-18 National Institute Of Advanced Industrial & Technology 網膜及び／又はブドウ膜疾患の予防乃至治療用点眼薬
KR101341359B1 (ko) 2004-10-01 2013-12-13 램스코르 인코포레이티드 편리하게 이식가능한 서방형 약물 조성물
US8541413B2 (en) 2004-10-01 2013-09-24 Ramscor, Inc. Sustained release eye drop formulations
US20080038316A1 (en) 2004-10-01 2008-02-14 Wong Vernon G Conveniently implantable sustained release drug compositions
ES2532997T3 (es) * 2005-04-22 2015-04-06 Elizabeth Stuart Uso de tocotrienoles de vitamina E para la inhibición del patógeno intracelular obligado Chlamydia
EP2043628A4 (en) 2006-06-27 2009-11-25 Riolan Technologies Inc ULTRAVIOLET ABSORBENT OPHTHALMIC COMPOSITIONS
ES2667945T3 (es) * 2007-10-08 2018-05-16 Aurinia Pharmaceuticals Inc. Composiciones oftálmicas que comprenden inhibidores de calcineurina o Inhibidores de mTOR
CN107468648A (zh) * 2008-10-09 2017-12-15 拉姆斯科股份有限公司 治疗干眼综合征的组合物和方法

Also Published As

Publication number Publication date
AU2009302167B2 (en) 2014-05-01
JP2012505244A (ja) 2012-03-01
EP2344155A4 (en) 2012-12-19
US9144566B2 (en) 2015-09-29
US9474736B2 (en) 2016-10-25
AU2009302167A1 (en) 2010-04-15
US20140200268A1 (en) 2014-07-17
US20100093845A1 (en) 2010-04-15
CN102238949A (zh) 2011-11-09
CA2739658C (en) 2016-11-08
CA2739658A1 (en) 2010-04-15
US8722728B2 (en) 2014-05-13
WO2010042843A3 (en) 2010-07-01
US20150359779A1 (en) 2015-12-17
JP5731980B2 (ja) 2015-06-10
JP2015120712A (ja) 2015-07-02
WO2010042843A2 (en) 2010-04-15
EP2344155B1 (en) 2017-09-06
AU2009302167B9 (en) 2014-05-29
EP2344155A2 (en) 2011-07-20
CN107468648A (zh) 2017-12-15

Similar Documents

Publication Publication Date Title
BRPI0920326A2 (pt) composição e método para tratamento da síndrome do olho ressecado
BRPI0911757A2 (pt) composiÇÕes e mÉtodos para tratar distérbios digestivos.
BRPI0819331A2 (pt) Métodos e composições para o tratamento do olho seco
BRPI0923883A2 (pt) Aparelho e método para combinação de componentes para artigos de fumar
BRPI0922122A2 (pt) composições e métodos para tratamento de doença celíaca.
BR112014014234A2 (pt) composição não colorante para tratar as fibras queratínicas e método para tratar as fibras queratínicas
BRPI0912867A2 (pt) composição de tratamento para lavagem e método caseiro para tratamento de têxteis
BRPI0807918A2 (pt) composições e método para preservação de tecido
BRPI0908854A2 (pt) composições e métodos para o tratamento de tumor de origem hematopoética
BRPI0919575A2 (pt) método, e, composição
BRPI0909627A2 (pt) métodos, composições e kits para tratar dores e pruridos
BRPI0920284A2 (pt) composição e método
BRPI1011325A2 (pt) composições e métodos para o tratamento de inflamação
BRPI0823277A2 (pt) Composição, e , método
FI20070935L (fi) Koostumus ja menetelmä puun käsittelemiseksi
PT2340042E (pt) Métodos e composições para o tratamento de cancro
BRPI1007600A2 (pt) composições e métodos para tratamento de doenças cardiovasculares
BRPI0916787A2 (pt) artigo, e, método para fabricar um artigo
BRPI0919813A2 (pt) aparelho de exercício e método para operar aparelho de exercício
BRPI0822349A2 (pt) composições e métodos para tratar doenças lisossômicas
BRPI0909164A2 (pt) método e composições para o tratamento de câncer
BRPI0921959A2 (pt) métodos e composições para remoção de tatuagem
BRPI1006145A2 (pt) "composição e método para tratamento de diabetes".
BRPI0911098A2 (pt) formulação lipossomal e método para tratamento de bexiga hiperativa.
BRPI0918646A2 (pt) aparelho e método para tratar choque acetebular femoral

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B06F Objections, documents and/or translations needed after an examination request according art. 34 industrial property law
B07E Notice of approval relating to section 229 industrial property law

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: suspension of the patent application procedure
B08F Application fees: dismissal - article 86 of industrial property law

Free format text: REFERENTE A 10A ANUIDADE.

B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements